Ozempic Face: What Causes It, How to Prevent It, and What Doctors Actually Recommend

What people mean by 'Ozempic face'

The term spread on social media as semaglutide became widely used for weight loss [3]. A 2024 dermatology commentary describes it as rapid facial weight loss leaving a distorted facial appearance, and frames the clinical question it raises: whether this is a new adverse effect or a natural consequence of fast weight loss [3]. Facial plastic surgeons describe the same picture, with facial volume and fat depleted and wrinkles and sagging skin appearing, and note that prescribers seldom raise the possibility with patients [5].

Ozempic is a diabetes drug; the weight-loss semaglutide is Wegovy

Ozempic is approved to improve glycemic control in adults with type 2 diabetes, to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce kidney and cardiovascular risk in type 2 diabetes with chronic kidney disease; it has no weight-loss indication [4]. Wegovy is the semaglutide product approved for weight management [3]. The phrase 'Ozempic face' is used for facial changes on semaglutide weight loss in general.

How much facial volume is actually lost?

A retrospective cohort at one academic medical center compared CT or MRI scans taken before and after patients started a GLP-1 agonist between 2017 and 2024 [1]. Twenty patients had usable imaging; median age was 54, average treatment duration 321 days, and average weight loss 11.0 kg [1]. Median total midface volume fell 9.0%; median superficial volume fell 11.0% and median deep volume 7.0%, with a wide spread in the deep compartment (interquartile range -20% to +15%) [1]. Superficial volume loss tracked kilograms lost (rho = 0.590, P = .006); deep volume loss did not (r = 0.115, P = .629) [1]. The regression estimate was about 7% of midface volume per 10 kg of weight lost [1]. It is a small single-center sample, and the results are reported for GLP-1 agonists as a group [1].

Fat loss may not be the whole story

A 2025 review proposes that GLP-1 receptor activity in skin-related cells could contribute to facial changes beyond fat loss. These mechanisms have not been established as the cause of facial changes in patients [6].

Skin changes that come with rapid loss

A 2026 systematic review of 40 human studies found that GLP-1-driven weight loss frequently alters skin morphology: facial volume loss, dermal thinning, loss of collagen and elastin fibers, reduced elasticity, and localized fat loss that leaves redundant skin folds [2]. It listed advanced age, a long history of obesity, rapid weight loss, poor hydration and insufficient protein intake as risk factors for more severe dermatological outcomes [2].

What prevention advice is actually supported

The 2026 review recommends gradual weight loss, adequate nutrition and hydration, and early dermatologic care. It lists poor hydration and insufficient protein intake among the risk factors for worse skin outcomes, and it calls for prospective studies to define the pathophysiology and management of GLP-1 receptor agonist-associated skin changes [2].

Fillers, skin tightening and surgery

The facial plastic surgery literature describes dermal fillers for volume restoration, skin-tightening techniques for laxity, and surgery for volume restoration and excess skin [5]. The 2026 review recommends early dermatologic input as part of a proactive approach [2].

One practical point if a procedure is planned: the Ozempic label warns about pulmonary aspiration during general anesthesia or deep sedation in patients taking GLP-1 receptor agonists and says patients should tell their healthcare providers about planned surgeries or procedures [4].

If semaglutide is stopped

The stopping data are for body weight. In STEP 4, 803 adults who completed a 20-week semaglutide run-in were randomized to continue semaglutide 2.4 mg or switch to placebo for 48 weeks; the continuing group lost a further 7.9% of body weight while the placebo group regained 6.9% [9]. In the STEP 1 extension, 327 participants regained 11.6 of the 17.3 percentage points they had lost within a year of stopping [10].